Your browser is no longer supported. Please, upgrade your browser.
Settings
KRTX Karuna Therapeutics, Inc. daily Stock Chart
KRTX [NASD]
Karuna Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.99 Insider Own29.80% Shs Outstand25.17M Perf Week-13.30%
Market Cap1.64B Forward P/E- EPS next Y-3.24 Insider Trans2.13% Shs Float18.50M Perf Month267.85%
Income-44.50M PEG- EPS next Q-0.53 Inst Own47.80% Short Float1.09% Perf Quarter284.97%
Sales- P/S- EPS this Y-190.30% Inst Trans53.73% Short Ratio0.36 Perf Half Y-
Book/sh7.10 P/B9.20 EPS next Y-42.70% ROA- Target Price103.25 Perf Year-
Cash/sh6.42 P/C10.18 EPS next 5Y- ROE- 52W Range11.24 - 152.00 Perf YTD226.32%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-57.02% Beta-
Dividend %- Quick Ratio106.90 Sales past 5Y- Gross Margin- 52W Low481.23% ATR10.35
Employees17 Current Ratio106.90 Sales Q/Q- Oper. Margin- RSI (14)55.21 Volatility7.88% 24.37%
OptionableNo Debt/Eq0.00 EPS Q/Q-35.20% Profit Margin- Rel Volume0.58 Prev Close67.63
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume558.62K Price65.33
Recom1.20 SMA204.43% SMA5093.96% SMA200153.24% Volume326,765 Change-3.40%
Jul-23-19Initiated Wells Fargo Outperform $29
Jul-23-19Initiated Wedbush Outperform $38
Jul-23-19Initiated Goldman Buy $34
Jul-23-19Initiated Citigroup Buy $28
Nov-26-19 07:00AM  Karuna Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference Business Wire -11.32%
Nov-20-19 06:58PM  Karuna Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock Business Wire -12.13%
09:31AM  Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More Zacks
Nov-19-19 04:20PM  Here's Why This Biotech Stock Has Septupled In Value Over Two Days Investor's Business Daily +29.16%
09:54AM  Company News For Nov 19, 2019 Zacks
07:56AM  The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout Benzinga
05:51AM  Dow Jones Futures: Can Software Rejoin Stock Market Rally? Apple Event Planned; These Stocks Are Moving On News Investor's Business Daily
Nov-18-19 04:21PM  Karuna Therapeutics Announces Proposed Public Offering of Common Stock Business Wire +442.99%
11:18AM  Karuna Therapeutics' stock more than triples after upbeat trial results of schizophrenia treatment MarketWatch
06:00AM  Karuna Therapeutics Announces KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia Business Wire
Nov-17-19 04:00PM  Karuna Therapeutics Schedules Webcast and Conference Call to Announce Results from its Phase 2 Clinical Trial of KarXT for the Treatment of Psychosis in Patients with Schizophrenia Business Wire
Nov-07-19 06:00AM  Karuna Therapeutics Reports Third Quarter 2019 Financial Results and Provides General Business Update Business Wire
Aug-28-19 08:00AM  Karuna Therapeutics to Present at Upcoming Investor Conferences Business Wire
Aug-08-19 06:00AM  Karuna Therapeutics Reports Second Quarter 2019 Financial Results and Provides General Business Update Business Wire +7.47%
Aug-06-19 08:00AM  Karuna Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference Business Wire -7.54%
Jul-02-19 07:15PM  Karuna Therapeutics Inc (KRTX) President & CEO Steven M Paul Bought $230,400 of Shares GuruFocus.com
04:01PM  Karuna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares Business Wire
Jun-28-19 11:32AM  Karuna Therapeutics Opens Above IPO Price Benzinga
Jun-27-19 05:44PM  Karuna Therapeutics Announces Pricing of Upsized Initial Public Offering Business Wire
04:37PM  Karuna Therapeutics IPO: What You Need To Know Benzinga
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical needs. The company's lead product candidate is KarXT, an oral modulator that is in Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia, as well as in Phase Ib clinical trial for the treatment of central nervous system disorders, such as cognitive and negative symptoms, Alzheimer's, and pain. It also focuses on developing other muscarinic-targeted drug candidates. Karuna Pharmaceuticals, Inc. has a license agreement with Eli Lilly and Company; and patent license agreement with PureTech Health LLC. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was founded in 2009 and is headquartered in Boston, Massachusetts. Karuna Therapeutics, Inc. operates as a subsidiary of PureTech Health plc.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HEALY JAMESDirectorNov 25Buy96.00156,25015,000,0001,885,602Nov 25 09:38 PM